A recent genetic study has provided new insights into how glucagon-like peptide-1 (GLP-1) receptor agonists aid weight loss.

Billy Joel has been performing his hit songs all over the world for decades, but a recent concert in Connecticut didn't go as ...

Obesity is a major risk factor for joint failure because excess weight puts more stress on the implants, leading to ...

Shares of WW International (NASDAQ:WW) have reversed Thursday’s after-hours gains as guarded remarks from the company’s CEO ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

Jab for joy? A landmark study of nearly 30,000 patients found that the use of GLP-1 medications, which include Wegovy and Ozempic, could have “an antidepressant effect,” suggesting ...

Health insurance companies are lobbying against proposals that would expand prescription access to weight-loss medications.